SBIR/STTR Research Award
Expanded Clinical Validation and Commercial Launch of the UriSeq Platform for Bladder Cancer
Award amount
$4,511,074Program and phase
SBIR · Phase IIAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Convergent Genomics, Inc.
- Proposal award date
- 2020-06-23
- Contract end date
- 2022-05-31
- UEI
- HAQGXY4K5956
- Solicitation number
- CA19-047
- Topic code
- NCI
Research abstract
Bladder cancer is the 5th most prevalent cancer with over 700,000 people living with the
disease in the US. The disease has a particularly high patient burden as it recurs in 70% of
patients following initial treatment. Over half of these patients do not respond or progress while
on treatment or surveillance. New therapeutic and diagnostic options are needed for patients
undergoing diagnosis and recurrence surveillance.This project is supporting the continued technical and clinical development of UriSeq, a
diagnostic test for bladder cancer. This project will support development of expanded clinical
validity, clinical utility and health economics on over 3,000 longitudinally monitored bladder
cancer patients.Project NarrativeThis project is supporting the continued technical and clinical development of UriSeq, a
diagnostic test for bladder cancer. This project will support development of expanded clinical
validity, clinical utility and health economics on over 3,000 longitudinally monitored bladder
cancer patients.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.
- SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
3 SBIR/STTR records share this UEI (2016–2020). Reported award amounts total $6,160,047. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services